This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Heparin in acute stroke

Authoring team

In the International stroke trial the group that received heparin had a significant 0.9% reduction in risk of recurrent stroke within 14 days. This was however counter balanced by a significant 0.8% increase in haemorrhagic stroke.

Trials involving low-molecular weight heparins, nadroparin and danaparoid have not convincingly shown benefit of these therapies.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.